Dynavax a compelling buy at current levels, says Jefferies Jefferies views Dynavax as a risky but compelling buy at current levels following the negative FDA panel vote on the company's hepatitis B vaccine. The firm lowered its price target for shares to $5 from $5 and keeps a Buy rating on the stock.
News For DVAX From The Last 14 Days
Check below for free stories on DVAX the last two weeks.
Subscribe for More Information